GlassScriptPhysician profile
John Patrick Dorsey
NPI 1114392800
$17,400.27
in general payments reported to CMS, 2019-2025
40 companies · $4,759 in 2025
The $4,759 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,837 · 2022: $1,825 · 2023: $4,208 · 2024: $4,772 · 2025: $4,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $63.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,675.00 |
| Education | $63.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,509.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,855.34 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,437.89 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $963.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $914.52 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $647.10 | 2021-2025 | |
| Genzyme Corporation | $607.03 | 2022-2025 | |
| Ardelyx, INC. | $546.40 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $535.38 | 2022-2025 | Dupixent |
| Pfizer INC. | $459.46 | 2021-2025 | |
| Lilly USA, LLC | $401.57 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $341.94 | 2023-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $261.66 | 2023-2025 | Voquezna |
| Celgene Corporation | $258.02 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $253.26 | 2021-2025 | Sucraid, Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $226.42 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $211.79 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $201.76 | 2021-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $195.60 | 2021-2025 | Cimzia, Rebyota |
| Ironwood Pharmaceuticals, INC | $182.62 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $180.19 | 2024-2025 | Vowst, Zenpep |
| Celltrion USA INC. | $143.46 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Daiichi Sankyo INC. | $124.07 | 2021-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $106.80 | 2024 | Dificid |
| Regeneron Pharmaceuticals, INC. | $106.67 | 2024 | Dupixent |
| Mylan Institutional INC. | $97.80 | 2023 | Hulio |
| Biocon Biologics INC | $89.21 | 2024-2025 | Yesintek, Hulio |
| Fresenius Kabi USA, LLC | $76.53 | 2023-2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $68.30 | 2024-2025 | Iqirvo, Bylvay |
| Amgen INC. | $55.76 | 2022-2025 | Avsola, Amjevita, Uplizna |
| Sandoz INC. | $49.97 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.94 | 2023-2024 | Cyltezo |
| Organon LLC | $47.92 | 2023 | Hadlima |
| Medtronic, INC. | $42.39 | 2024 | Interstim |
| Exact Sciences Corporation | $37.85 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Blueprint Medicines Corporation | $34.71 | 2023 | |
| Csl Behring | $23.13 | 2023 | Kcentra |
| Redhill Biopharma INC. | $21.36 | 2021 | |
| Lucid Diagnostics INC. | $20.87 | 2025 | |
| Alfasigma USA, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dorsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.